文献速递皮肤肿瘤

Sonidegib与Vismodegib治疗局部晚期基底细胞癌:联合专家意见

Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-03-04

Sonidegib和vismodegib均为获批治疗晚期基底细胞癌的Hedgehog通路抑制剂。由于缺乏头对头随机对照试验,且关键研究BOLT与ERIVANCE设计存在差异,本文汇总专家意见比较两者临床与药理特征。经RECIST类似标准调整后,sonidegib客观缓解率60.6%,vismodegib为47.6%,两者疗效与耐受性相似但药代动力学存在差异。

要点

  • 两种HhI疗效与耐受性相似,但缺乏头对头随机对照试验。
  • BOLT与ERIVANCE设计差异影响疗效比较,需标准调整。
  • 药代动力学差异如分布容积和半衰期可能影响临床实践。

核心结论

  • Sonidegib与vismodegib在局部晚期基底细胞癌中疗效与耐受性相似,但药代动力学存在差异。

研究设计与样本

  • 基于已发表数据和专家临床经验的联合专家意见,比较sonidegib与vismodegib的临床和药理特征。

主要发现

  • Vismodegib经RECIST中心评审21个月随访客观缓解率为47.6%(95%CI:35.5-60.6)。
  • Sonidegib经RECIST类似标准调整后18个月随访中心评审客观缓解率为60.6%(95%CI:47.8-72.4)。
  • 两种治疗不良事件模式相似,但药代动力学如分布容积和半衰期存在差异。

临床怎么用

  • 在手术和放疗不适用时,sonidegib可作为vismodegib的替代治疗选择。

局限性

  • 无头对头随机对照试验,关键研究设计差异使相对疗效和安全性分析复杂化。
  • 需进一步研究药代动力学差异对临床实践的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sonidegib and vismodegib are hedgehog pathway inhibitors (HhIs) approved for the treatment of advanced basal cell carcinoma (BCC). Until recently, vismodegib was the only targeted treatment available for patients with locally advanced BCC (laBCC) in cases where surgery and radiotherapy are inappropriate. Sonidegib has recently been approved and now presents an alternative treatment option. The clinical differences between the two HhIs in patients with laBCC are unclear, as no head-to-head randomized controlled trials are or will be initiated. Moreover, there were important differences in the designs of their pivotal studies, BOLT (sonidegib) and ERIVANCE (vismodegib), and these differences complicate evidence-based analysis of their relative efficacy and safety profiles. In this paper, a group of clinical experts in the management of laBCC summarizes the clinical and pharmacological profiles of sonidegib and vismodegib based on published data and their own clinical experience. One key difference between the two pivotal studies was the criteria used to assess BCC severity. ERIVANCE (a single-arm phase II trial) used the conventional Response Evaluation Criteria in Solid Tumors (RECIST), while the more recent double-blind randomized BOLT trial used the stringent modified RECIST. A preplanned analysis adjusted the outcomes from BOLT with RECIST-like criteria, and this enabled the experts to discuss relative efficacy outcomes for the two treatments. Centrally reviewed objective response rate (ORR) for vismodegib was 47.6% (95% CI: 35.5-60.6) at 21-month follow-up using RECIST. After adjusting with RECIST-like criteria, the ORR for sonidegib according to central review at 18-month follow-up was 60.6% (95% CI: 47.8-72.4). Both treatments were associated with similar patterns of adverse events. Sonidegib and vismodegib share the same efficacy and tolerability profiles, but their pharmacokinetic profiles show several differences, such as volume of distribution and half-life. Further studies are needed to understand how these differences may impact clinical practice.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Dummer R, Ascierto PA, Basset-Seguin N, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020. PMID: 31990414. doi:10.1111/jdv.16230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。